Status:
ACTIVE_NOT_RECRUITING
Photobiomodulation Therapy in the Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy
Lead Sponsor:
Jessa Hospital
Conditions:
Chemotherapy-induced Peripheral Neuropathy
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This study aims to investigate the effectiveness of photobiomodulation therapy (PBM) in the management of chemotherapy-induced peripheral neuropathy (CIPN). Therefore, the hypothesis is that PBM can r...
Detailed Description
Chemotherapy-induced peripheral neuropathy (CIPN) is one of the common complications of cancer treatment and involves paresthesia, numbness and/or burning pain in distal limbs. This condition has a hi...
Eligibility Criteria
Inclusion
- Finished one of the following types of chemotherapy: paclitaxel, docetaxel, oxaliplatin, cisplatin, vincristine, thalidomide and/or bortezomib.
- Diagnosed with CIPN
- Age 18 years or above
- Have no documented or observable psychiatric or neurological disorders that might interfere with study participation (e.g., dementia or psychosis)
- Dutch-speaking
- Signed informed consent
Exclusion
- Taking stable doses of medication on prescription for peripheral neuropathy. Related medications are: gabapentin, pregabalin (Lyrica), nortriptyline, amitriptyline, duloxetine (Cymbalta), and venlafaxine.
- Severe or unstable cardio- respiratory or musculoskeletal disease
- Interruption of more than two consecutive laser treatments
- Dark brown or black skin pigmentation (described as skin type VI in the Fitzpatrick scale)
Key Trial Info
Start Date :
January 31 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 10 2028
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05199389
Start Date
January 31 2022
End Date
November 10 2028
Last Update
March 6 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jessa Hospital
Hasselt, Limburg, Belgium, 3500